Serina Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except par value amounts)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $23,024 | $3,056 |
| Prepaid expenses and other current assets | 2,006 | 3,024 |
| Total current assets | 25,030 | 6,080 |
| Property and equipment, net | 482 | 465 |
| Right of use assets - operating leases | 277 | 377 |
| Other long-term prepaid assets | 25 | 29 |
| TOTAL ASSETS | $25,814 | $6,951 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $1,858 | $1,931 |
| Accrued expenses | 1,359 | 1,207 |
| Warrant liability | — | 88 |
| Other current liabilities | 545 | 337 |
| Total current liabilities | 3,762 | 3,563 |
| Warrant liability, non-current | 113 | 283 |
| Convertible Note, net | 3,087 | 2,946 |
| Operating lease liabilities, net of current portion | 122 | 196 |
| TOTAL LIABILITIES | 7,084 | 6,988 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity (deficit): | ||
| Series A convertible preferred stock, $0.0001 par value, 5,000 shares authorized; zero and 965 issued and outstanding at June 30, 2026 and December 31, 2025, respectively; liquidation preference of $0 and $5,000 at June 30, 2026 and December 31, 2025, respectively | — | 4,940 |
| Common stock, $0.0001 par value, 125,000 and 40,000 shares authorized; 25,400 and 10,767 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 3 | 1 |
| Additional paid-in capital | 95,481 | 58,536 |
| Accumulated other comprehensive loss | — | (14) |
| Accumulated deficit | (76,754) | (63,500) |
| TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | 18,730 | (37) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $25,814 | $6,951 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.